证券日报网讯1月27日，易瑞生物（300942）在互动平台回答投资者提问时表示，公司已战略性收缩体 外诊断业务，暂无尼帕病毒的相关检测产品。目前公司专注于食品安全检测业务的稳步发展，并大力拓 展动物诊断业务。 ...

1月26日，易瑞生物大宗交易成交23万股，成交额219.42万元，占当日总成交额的0.86%，成交价9.54 元，较市场收盘价10.86元折价12.15%。 | 权益类证券大宗交易(协议交易) | | | | | | | 团 下载 | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 (万股/万份) | 成交金额 (万元) | 买方营业部 | 卖方营业部 | | 2026-01-26 | 300942 | 易瑞生物 | 9.54 | 23.00 | 219.42 机构专用 | | 东兴证券股份有限 公司上海陆家嘴证 券营业部 | ...

Group 1 - On January 20, 2026, a block trade of 300,000 shares of Easybio was executed, with a transaction amount of 2.73 million yuan, accounting for 3.74% of the total transaction volume for the day [1][2] - The transaction price was 9.1 yuan per share, which represents a discount of 9.9% compared to the market closing price of 10.1 yuan [1][2]

Group 1 - The core point of the article highlights the trading activity of Yirui Biological, which saw a closing price increase of 1.09% to 10.22 yuan on January 19 [1] - A significant block trade occurred, with a total volume of 300,000 shares and a transaction amount of 2.7 million yuan, at a price of 9.00 yuan per share, reflecting a premium rate of -11.94% [1] - Over the past three months, Yirui Biological has recorded 17 block trades, with a cumulative transaction amount of 52.11 million yuan [1] Group 2 - In the last five trading days, the stock has seen a cumulative increase of 0.20%, while the main capital has experienced a net outflow of 14.56 million yuan [1]

Core Viewpoint - Easybio announced the release of a pledge of 20 million shares by its controlling shareholder, Easybio (Hainan) Venture Capital Co., Ltd. on January 12, 2026 [2] Group 1 - The controlling shareholder, Easybio (Hainan) Venture Capital Co., Ltd., has released a pledge of 20 million shares [2]

Core Viewpoint - The company, EasyRegen Biotech, announced the release of a portion of shares pledged by its controlling shareholder, EasyRegen (Hainan) Venture Capital Co., Ltd, indicating a positive development in shareholder equity management [1] Group 1: Share Pledge Release - The number of shares released from pledge amounts to 20 million shares, which represents 16.12% of the shares held by the controlling shareholder [1] - The released shares account for 4.94% of the company's total share capital [1] Group 2: Remaining Pledged Shares - After the release, the total number of pledged shares by the controlling shareholder and its concerted parties is 33.9 million shares, which constitutes 8.37% of the company's current total share capital [1]

| 证券代码：300942 | 证券简称：易瑞生物 | 公告编号：2026-003 | | --- | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | | 深圳市易瑞生物技术股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市易瑞生物技术股份有限公司（以下简称"公司"）近日收到控股股 东易瑞（海南）创业投资有限公司的通知，获悉其所持有公司的部分股份办理 了解除质押业务，具体事项如下： | 股东名称 | 是否为控股股 东或第一大股 东及其一致行 | 本次解除质 押股份数量 | 占其所持 股份比例 | 占公司总 股本比例 | 质押起 始日 | 解除质 押日 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 动人 | （股） | | | | | | | 易瑞（海 | | | | | | | 深圳市中 | | 南）创业投 | 是 | 20,000,000 | 16.12% | 4.94% | 2025年4 | 2 ...

| 证券代码：300942 | 证券简称：易瑞生物 | 公告编号：2026-002 | | --- | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | | 深圳市易瑞生物技术股份有限公司 关于控股股东及其一致行动人权益变动 触及 1%整数倍的提示性公告 公司控股股东及其一致行动人保证向本公司提供的信息内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 深圳市易瑞生物技术股份有限公司（以下简称"公司"或"本公司"）于 2025 年 10 月 13 日披露了《关于控股股东及其一致行动人减持股份的预披露公 告》（公告编号：2025-069），控股股东易瑞（海南）创业投资有限公司（以下 简称"易瑞创投"）及其一致行动人深圳易达瑞管理咨询合伙企业（有限合伙） （以下简称"易达瑞"）和深圳易凯瑞管理咨询合伙企业（有限合伙）（以下简 称"易凯瑞"）计划于上述公告披露之日起 15 个交易日后的 3 个月内以集中竞 价或大宗交易方式减持公司股份，具体情况如下： 1、持有公司股份 132,369,971 股（占公司总股本 ...

Group 1 - The core viewpoint of the article is that Erye Biological (300942) currently has no business layout in the brain-computer interface field [1] Group 2 - The company responded to investor inquiries on its interactive platform [1] - The date of the announcement was January 6 [1]

Group 1 - The company, Erye Biotechnology (300942.SZ), currently has no business involvement in the brain-computer interface sector [1]